Reversible Anticholinesterases Pipeline Insight Report 2018: Products by Developmental Stage, Product Type, Molecule Type, and Administration Route - ResearchAndMarkets.com
DUBLIN--(BUSINESS WIRE)--Sep 6, 2018--The “Reversible Anticholinesterases -Pipeline Insight, 2018” drug pipelines has been added to ResearchAndMarkets.com’s offering.
‘Reversible Anticholinesterases - Pipeline Insight, 2018’ report offers comprehensive insights of the pipeline (under development) therapeutics scenario and growth prospects across Reversible Anticholinesterases development.
Descriptive coverage of pipeline development activities for Reversible Anticholinesterases - Pipeline therapeutics development coverage provides descriptive product profiles including (but not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details.
The report assesses the active Reversible Anticholinesterases pipeline products by developmental stage, product type, molecule type, and administration route.
Key Topics Covered:
1. Report Introduction
2. Reversible Anticholinesterases - Overview
3. Pipeline TherapeuticsAn Overview of Pipeline Products for Reversible Anticholinesterases
4. Comparative Analysis
5. Reversible Anticholinesterases Pipeline Products in Clinical StagesProduct Description Research and Development Product Development Activities
6. Reversible Anticholinesterases Pipeline Products in Non-clinical StagesProduct Description Research and Development Product Development Activities
7. Therapeutic Assessment: Active ProductsPipeline Assessment by Route of Administration Pipeline Assessment by Stage and Route of Administration Pipeline Assessment by Molecule Type Pipeline Assessment by Stage and Molecule Type 8. Inactive Pipeline ProductsProduct DescriptionResearch and DevelopmentProduct Development ActivitiesReason for dormancy/discontinuation
Companies MentionedAxovant SciencesDeuteRxLuye PharmaRaptor Pharmaceutical CorpAnavex Life SciencesAstellas PharmaNovartisEisai Co LtdJanssen Pharmaceutical KKFor more information about this drug pipelines report visit https://www.researchandmarkets.com/research/mgw9xz/reversible?w=4
View source version on businesswire.com:https://www.businesswire.com/news/home/20180906005911/en/
Laura Wood, Senior Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics:Cardiovascular Drugs
INDUSTRY KEYWORD: HEALTH CARDIOLOGY PHARMACEUTICAL
SOURCE: Research and Markets
Copyright Business Wire 2018.
PUB: 09/06/2018 04:01 PM/DISC: 09/06/2018 04:01 PM